We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Eli Lilly Licenses Rigel’s Experimental Anti-Inflammatory Drug for Up to $960 Million
Eli Lilly Licenses Rigel’s Experimental Anti-Inflammatory Drug for Up to $960 Million
Eli Lilly has inked a global licensing deal with Rigel Pharmaceuticals for the company’s investigational anti-inflammatory drug, R552, in a pact worth potentially $960 million.